Celator Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELATOR PHARMS, and what generic alternatives to CELATOR PHARMS drugs are available?
CELATOR PHARMS has one approved drug.
There are nine US patents protecting CELATOR PHARMS drugs.
There are one hundred and twenty-six patent family members on CELATOR PHARMS drugs in twenty-six countries and thirty-six supplementary protection certificates in sixteen countries.
Drugs and US Patents for Celator Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,518,437 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,022,279 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 8,092,828 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 10,166,184 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Celator Pharms | VYXEOS | cytarabine; daunorubicin | POWDER;INTRAVENOUS | 209401-001 | Aug 3, 2017 | RX | Yes | Yes | 9,271,931 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celator Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 102284689 | ⤷ Try a Trial |
European Patent Office | 1432402 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 03028696 | ⤷ Try a Trial |
Croatia | P20191683 | ⤷ Try a Trial |
Netherlands | 300960 | ⤷ Try a Trial |
Denmark | 1432402 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celator Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1744764 | 2018/042 | Ireland | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823 |
3300601 | 22C1034 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
2768484 | 19C1063 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE DAUNORUBICINE ET CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827 |
3300601 | 2022C/528 | Belgium | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827 |
2768484 | CR 2019 00051 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
2768484 | CA 2019 00051 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF DAUNORUBICIN OG CYTARABIN; REG. NO/DATE: EU/1/18/1308 20180827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.